Cargando…
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
BACKGROUND: Triple-negative (TN) breast cancers exhibit major initial responses to neoadjuvant chemotherapy, but generally have a poor outcome. Because of the lack of validated drug targets, chemotherapy remains an important therapeutic tool in these cancers. METHODS: We report the survival of two c...
Autores principales: | Giacchetti, S, Porcher, R, Lehmann-Che, J, Hamy, A-S, de Roquancourt, A, Cuvier, C, Cottu, P-H, Bertheau, P, Albiter, M, Bouhidel, F, Coussy, F, Extra, J-M, Marty, M, de Thé, H, Espié, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960631/ https://www.ncbi.nlm.nih.gov/pubmed/24569467 http://dx.doi.org/10.1038/bjc.2014.81 |
Ejemplares similares
-
HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
por: Groheux, D, et al.
Publicado: (2013) -
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
por: Cottu, P H, et al.
Publicado: (2001) -
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
por: Lehmann-Che, Jacqueline, et al.
Publicado: (2013) -
Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007) -
Prognostic Impact of Stromal Immune Infiltration before and after Neoadjuvant Chemotherapy (NAC) in Triple Negative Inflammatory Breast Cancers (TNIBC) Treated with Dose-Dense Dose-Intense NAC
por: Campedel, Luca, et al.
Publicado: (2020)